Principal Financial Group Inc. Invests $100,000 in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Principal Financial Group Inc. bought a new stake in Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 35,088 shares of the company’s stock, valued at approximately $100,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ORGO. Tower Research Capital LLC TRC boosted its holdings in shares of Organogenesis by 94.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock valued at $27,000 after acquiring an additional 3,235 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Organogenesis during the 4th quarter worth about $43,000. Palumbo Wealth Management LLC purchased a new position in shares of Organogenesis during the 4th quarter valued at about $46,000. Capital Square LLC lifted its holdings in shares of Organogenesis by 23.8% in the 4th quarter. Capital Square LLC now owns 20,450 shares of the company’s stock valued at $84,000 after buying an additional 3,930 shares during the period. Finally, SG Americas Securities LLC boosted its stake in shares of Organogenesis by 23.2% in the fourth quarter. SG Americas Securities LLC now owns 35,774 shares of the company’s stock worth $146,000 after buying an additional 6,727 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital started coverage on Organogenesis in a research report on Friday, June 28th. They issued a “buy” rating and a $5.00 price objective on the stock.

View Our Latest Stock Report on ORGO

Organogenesis Price Performance

NASDAQ:ORGO opened at $2.81 on Tuesday. The company has a quick ratio of 2.41, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Organogenesis Holdings Inc. has a 52 week low of $1.96 and a 52 week high of $4.70. The stock’s 50-day moving average price is $2.64 and its 200-day moving average price is $3.08. The stock has a market capitalization of $372.52 million, a PE ratio of 70.27 and a beta of 1.64.

Organogenesis (NASDAQ:ORGOGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Organogenesis had a return on equity of 2.11% and a net margin of 1.34%. The company had revenue of $109.98 million for the quarter, compared to analyst estimates of $100.44 million. During the same period last year, the company earned ($0.02) earnings per share. As a group, equities analysts expect that Organogenesis Holdings Inc. will post -0.05 EPS for the current fiscal year.

Organogenesis Profile

(Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

See Also

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.